We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy.
- Authors
Lindahl, Hannes; Norlin, Anna-Carin; Bergman, Peter
- Abstract
Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 commercial immunoglobulin batches and show that there are consistent product-specific differences in the levels of HBV core antigen antibodies and that choice of immunoglobulin product may have an impact on false-positivity rates.
- Subjects
HEPATITIS B virus; SEROTHERAPY; CONSUMER preferences; DISEASE risk factors; SEROLOGY
- Publication
Open Forum Infectious Diseases, 2023, Vol 10, Issue 11, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofad551